Ticagrelor Monotherapy After Stenting - Trial NCT05149560
Access comprehensive clinical trial information for NCT05149560 through Pure Global AI's free database. This Phase 2 trial is sponsored by Vastra Gotaland Region and is currently Recruiting. The study focuses on Acute Myocardial Infarction. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vastra Gotaland Region
Timeline & Enrollment
Phase 2
Dec 04, 2021
Dec 15, 2024
Primary Outcome
Major adverse cardiac event
Summary
A pilot study planned to evaluate initial safety of ticagrelor monotherapy after coronary
 stenting due to acute myocardial infarction.
 
 The study is a single-centre, single-arm, prospective phase II study 200 patients who undergo
 coronary artery stenting due to NSTEMI or STEMI will be included.
 
 Primary endpoint (variable):
 
 The composite of cardiac death, spontaneous myocardial infarction or definite or probable
 stent thrombosis within 3 months.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05149560
Non-Device Trial